In today’s briefing:
- China Healthcare Weekly (Jan.1) – NRDL Negotiation Turnaround, Pullback of TCM, Biotech Sales System
- The Innovations Portfolios – Week Six
China Healthcare Weekly (Jan.1) – NRDL Negotiation Turnaround, Pullback of TCM, Biotech Sales System
- This year’s NRDL negotiations could be a turnaround. If the final result really shows a moderate price decline, it will be “a landmark event” for the innovative drug industry.
- Starting from 23Q2, with the peak of respiratory disease/COVID-19 outbreak past, the demand for related TCM would weaken. Then, the pullback of TCM would really begin.
- Even if biotech initially tells the story of becoming a biopharma to obtain financing, it will not be realized in the end.
The Innovations Portfolios – Week Six
- We again write about one stock each from the large, mid and small cap portfolios, briefly giving the reasons behind their inclusion.
- The three companies we write about this week are Samsung Electronics (005930 KS) , Schlumberger Ltd (SLB US) and Whirlpool Corp (WHR US)
- For the six weeks ended 30 Dec the combined innovation portfolio was -1.7, versus DJIA -1.8%, S&P500 -3.2%, Nasdaq -6.1% & MSCI-ACWI-ETF -2.4%, all in US$ terms
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
